Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...

A new Ohio University study offers a glimmer of hope in the fight against lung cancer. Monica Robins has that story and more ...

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other ...

Investing.com -- Novo Nordisk announced late Friday that the US Food and Drug Administration has approved three new indications for once-weekly Sogroya (somapacitan-beco) injection 5 mg, 10 mg, or 15 ...

Explore new strategies for treating resistant lung cancer. Discover how blocking growth hormone receptors may improve ...

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments. The study published in the International Journal of Molecular Science ...

FDA expands Sogroya approval for pediatric patients with Noonan syndrome, idiopathic short stature, and those born small for gestational age.

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments. The study published ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya® (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments. The study published in the International Journal of Molecular Science ...

Touted by some as a miracle cure-all, stacking is attracting attention for another reason, too: a lack of long-term data and ...

Navepegritide is indicated for those ages 2 and older with open epiphyses ...